|
Affiliation |
Faculty of Medicine School of Medicine Department of Internal Medicine, Hematology, Respirology, Rheumatology, Infectious Diseases, and Neurology |
|
Title |
Professor |
|
External Link |
|
|
Related SDGs |
|
MIYAZAKI Taiga
|
|
|
Papers 【 display / non-display 】
-
A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19. Reviewed
Miyazaki T, Hosogaya N, Fukushige Y, Takemori S, Morimoto S, Yamamoto H, Hori M, Ozawa Y, Shiko Y, Inaba Y, Kurokawa T, Hanaoka H, Iwanami S, Kim K, Iwami S, Watashi K, Miyazawa K, Umeyama T, Yamagoe S, Miyazaki Y, Wakita T, Sumiyoshi M, Hirayama T, Izumikawa K, Yanagihara K, Mukae H, Kawasuji H, Yamamoto Y, Tarumoto N, Ishii H, Ohno H, Yatera K, Kakeya H, Kichikawa Y, Kato Y, Matsumoto T, Saito M, Yotsuyanagi H, Kohno S.
Microbiol Spectr 11 ( 3 ) e0431122 2023.6
Publishing type：Research paper (scientific journal)
-
Miyazaki T, Hosogaya N, Fukushige Y, Takemori S, Morimoto S, Yamamoto H, Hori M, Ozawa Y, Shiko Y, Inaba Y, Kurokawa T, Hanaoka H, Iwanami S, Kim K, Iwami S, Watashi K, Miyazawa K, Umeyama T, Yamagoe S, Miyazaki Y, Wakita T, Sumiyoshi M, Hirayama T, Izumikawa K, Yanagihara K, Mukae H, Kawasuji H, Yamamoto Y, Tarumoto N, Ishii H, Ohno H, Yatera K, Kakeya H, Kichikawa Y, Kato Y, Matsumoto T, Saito M, Yotsuyanagi H, Kohno S
Microbiology spectrum 11 ( 3 ) e0431122 2023.5
Authorship：Lead author, Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：Microbiology Spectrum
Nelfinavir, an orally administered inhibitor of human immunodeficiency virus protease, inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) in vitro. We conducted a randomized controlled trial to evaluate the clinical efficacy and safety of nelfinavir in patients with SARS-CoV-2 infection. We included unvaccinated asymptomatic or mildly symptomatic adult patients who tested positive for SARS-CoV-2 infection within 3 days before enrollment. The patients were randomly assigned (1:1) to receive oral nelfinavir (750 mg; thrice daily for 14 days) combined with standard-of-care or standard-of-care alone. The primary endpoint was the time to viral clearance, confirmed using quantitative reverse-transcription PCR by assessors blinded to the assigned treatment. A total of 123 patients (63 in the nelfinavir group and 60 in the control group) were included. The median time to viral clearance was 8.0 (95% confidence interval [CI], 7.0 to 12.0) days in the nelfinavir group and 8.0 (95% CI, 7.0 to 10.0) days in the control group, with no significant difference between the treatment groups (hazard ratio, 0.815; 95% CI, 0.563 to 1.182; P = 0.1870). Adverse events were reported in 47 (74.6%) and 20 (33.3%) patients in the nelfinavir and control groups, respectively. The most common adverse event in the nelfinavir group was diarrhea (49.2%). Nelfinavir did not reduce the time to viral clearance in this setting. Our findings indicate that nelfinavir should not be recommended in asymptomatic or mildly symptomatic patients infected with SARS-CoV-2. The study is registered with the Japan Registry of Clinical Trials (jRCT2071200023). IMPORTANCE The anti-HIV drug nelfinavir suppresses the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro. However, its efficacy in patients with COVID-19 has not been studied. We conducted a multicenter, randomized controlled trial to evaluate the efficacy and safety of orally administered nelfinavir in patients with asymptomatic or mildly symptomatic COVID-19. Compared to standard-of-care alone, nelfinavir (750 mg, thrice daily) did not reduce the time to viral clearance, viral load, or the time to resolution of symptoms. More patients had adverse events in the nelfinavir group than in the control group (74.6% [47/63 patients] versus 33.3% [20/60 patients]). Our clinical study provides evidence that nelfinavir, despite its antiviral effects on SARSCoV-2 in vitro, should not be recommended for the treatment of patients with COVID-19 having no or mild symptoms.
-
Nakada-Motokawa N, Miyazaki T, Ueda T, Yamagishi Y, Yamada K, Kawamura H, Kakeya H, Mukae H, Mikamo H, Takesue Y, Kohno S
Mycoses 64 ( 12 ) 1498 - 1507 2021.12
Authorship：Corresponding author Language：Japanese Publishing type：Research paper (scientific journal) Publisher：Mycoses
Background: Several severity indexes have been reported for critically ill patients. The Pitt bacteremia score (PBS) is commonly used to predict the risk of mortality in patients with bacteraemia. Objectives: To develop a scoring system for predicting mortality in candidaemia patients. Methods: Medical records at five Japanese tertiary hospitals were reviewed. Factors associated with mortality were analysed using logistic regression modelling. The discriminatory power of scoring models was evaluated by assessing the area under the receiver operating characteristic curve (AUC), net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Results: In total, 422 candidaemia patients were included. Higher PBS, dialysis and retainment of central venous catheter were independent risk factors for all-cause 30-day mortality. However, among the five PBS components, fever was not associated with mortality; therefore, we developed a modified version of the PBS (mPBS) by replacing fever with dialysis. AUC for PBS and mPBS were 0.74 (95% confidence interval [CI]: 0.68–0.80) and 0.76 (95% CI: 0.71–0.82), respectively. The increase in predictive ability of mPBS for 30-day mortality was statistically significant as assessed by NRI (0.24, 95% CI: 0.01–0.46, p =.04) and IRI (0.04, 95% CI: 0.02–0.06, p =.0008). When patients were stratified by mPBS into low (scores 0–3), moderate (4–7) and high risk (≥8), there were significant differences among the survival curves (p <.0001, log-rank test), and 30-day mortality rates were 13.8% (40/290), 36.8% (28/76) and 69.4% (34/49), respectively. Conclusions: mPBS can be a useful tool for predicting mortality in candidaemia patients.
DOI： doi:10.1111/myc.13380. Epub 2021 Oct 23. PMID: 34655487.
-
Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection. Reviewed
Kim KS, Iwanami S, Oda T, Fujita Y, Kuba K, Miyazaki T, Ejima K, Iwami S
Life Sci Alliance 4 ( 10 ) e202101049 2021.8
Publishing type：Research paper (scientific journal)
DOI： doi:10.26508/lsa.202101049. PMID: 34344719; PMCID: PMC8340032.
-
Revisiting the guidelines for ending isolation for COVID-19 patients. Reviewed
Jeong YD, Ejima K, Kim KS, Iwanami S, Bento AI, Fujita Y, Jung IH, Aihara K, Watashi K, Miyazaki T, Wakita T, Iwami S, Ajelli M.
Elife 10 e69340 2021.7
Publishing type：Research paper (scientific journal)
DOI： doi:10.7554/eLife.69340. PMID: 34311842; PMCID: PMC8315804.
Books 【 display / non-display 】
-
最新の臨床WEB
坪内拡伸（ Role： Contributor , 喘息発作）
南江堂 2024.3
Total pages：web Responsible for pages：web Book type：Scholarly book
-
最新の臨床WEB
坪内拡伸（ Role： Contributor , アレルギー性気管支肺真菌症（ABPM））
南江堂 2024.3
Total pages：web Responsible for pages：web Book type：Scholarly book
-
臨床と研究
住吉 誠、宮崎泰可（ Role： Contributor , 【各種疾患における薬剤選択と使い方】肺炎・気管支炎）
大道学館 2024.3
Responsible for pages：101(3):279-285 Book type：Scholarly book
-
ウイルス感染の数理モデルとシミュレーション―データを定量的に理解する―
平山達朗、宮崎泰可（ Role： Contributor , 生物コラム10 新型コロナウイルスの臨床について）
共立出版 2024.2
Total pages：304 Book type：Scholarly book
-
神経内科
塩見一剛（ Role： Contributor , 専門医試験問題 解答と解説 第2集）
南江堂 2024.2
Total pages：201 Book type：Textbook, survey, introduction
MISC 【 display / non-display 】
-
話題のくすり「イサブコナゾール」.
髙城一郎, 宮崎泰可
日本病院薬剤師会雑誌 60 ( 2 ) 178 - 180 2024.2
Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
市中肺炎 Reviewed
住吉 誠、宮崎泰可
日本内科学会雑誌 112 ( 11 ) 2053 - 2058 2023.11
Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
特集 呼吸器感染症のアンメットニーズを探る IV.COVID-19 コロナ禍での深在性真菌症の疫学と病態
住吉 誠、宮崎泰可
呼吸器ジャーナル 71 ( 4 ) 560 - 566 2023.11
Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
肺炎球菌感染症に対する予防戦略 −宮崎県の現状と今後の展望を含めて−
宮崎泰可
宮崎県医師会医学会誌 47 ( 1 ) 7 - 11 2023.3
Publishing type：Article, review, commentary, editorial, etc. (scientific journal)
-
Candida auris
平山達朗、宮崎泰可
臨床と微生物 特集 Priority Pathogen List (PPL) に取り上げられる耐性菌 50 ( 1 ) 74 - 79 2023.1
Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)
Presentations 【 display / non-display 】
-
肺炎に類似する症状や胸部画像所見を呈した悪性リンパ腫の一例
増田樹、山本哲平、小田康晴、唐澤賢祥、上運天綾子、北村彩、北村瑛子、住吉誠、坪内拡伸、柳重久、宮崎泰可
第92回日本呼吸器学会・日本結核 非結核性抗酸菌症学会九州支部 春季学術講演会 2024.3.16
Event date： 2024.3.16
Presentation type：Oral presentation (general)
-
過敏性肺炎の合併が示唆され、進行性の肺線維化をきたした自己免疫性肺胞蛋白症の一例
長濱薫、末原照大、横尾優希、山成康洋、北村瑛子、住吉誠、小田康晴、坪内拡伸、柳重久、宮崎泰可
第92回日本呼吸器学会・日本結核 非結核性抗酸菌症学会九州支部 春季学術講演会 2024.3.16
Event date： 2024.3.16
Presentation type：Oral presentation (general)
-
過敏性肺炎の合併が示唆され、進行性の肺線維化をきたした自己免疫性肺胞蛋白症の一例
長濱薫、末原照大、横尾優希、山成康洋、北村瑛子、住吉誠、小田康晴、坪内拡伸、柳重久、宮崎泰可
第92回日本呼吸器学会・日本結核 非結核性抗酸菌症学会九州支部 春季学術講演会 2024.3.16
Event date： 2024.3.16
Presentation type：Oral presentation (general)
-
肺炎に類似する症状や胸部画像所見を呈した悪性リンパ腫の一例
増田樹、山本哲平、小田康晴、唐澤賢祥、上運天綾子、北村彩、北村瑛子、住吉誠、坪内拡伸、柳重久、宮崎泰可
第92回日本呼吸器学会・日本結核 非結核性抗酸菌症学会九州支部 春季学術講演会 2024.3.16
Event date： 2024.3.16
Presentation type：Oral presentation (general)
-
医原性免疫不全関連リンパ増殖性疾患が再燃し、びまん性大細胞型B 細胞リンパ腫を発症した関節リウマチ
佐々木悠、岩尾浩昭、工藤理紗、木村賢俊、力武雄幹、相澤彩子、仮屋裕美、 川口 剛、松田基弘、宮内俊一、髙城一郎、梅北邦彦、宮崎泰可、大栗伸行、 盛口淸香
第67回九州リウマチ学会 2024.3.2
Event date： 2024.3.2 - 2024.3.3
Presentation type：Oral presentation (general)
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
尿中蛋白質断片の網羅的解析による日和見感染症の新規診断法の開発
Grant number：22K08583 2022.04 - 2025.03
独立行政法人日本学術振興会 科学研究費基金 基盤研究(C)
Authorship：Principal investigator
-
病原真菌カンジダにおける多剤耐性機序の解明とその克服
Grant number：19K07540 2019.04 - 2022.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
Available Technology 【 display / non-display 】
-
各種感染症に対する検査法や治療法の開発を目指した臨床研究
地域医療への貢献を目指した肺炎の疫学研究
難治性真菌感染症の病態解明と創薬研究Home Page： 宮崎大学医学部内科学講座呼吸器・膠原病・感染症・脳神経内科学分野
Related fields where technical consultation is available：・ 感染症臨床研究の立案、実施
・ 病原真菌の分子生物学的解析Message：基礎と臨床の相互フィードバックで相乗効果を生み出すために、多分野連携による研究体制の構築を目指しています。